Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
BörsenkürzelSENS
Name des UnternehmensSenseonics Holdings Inc
IPO-datumMar 04, 2015
CEOGoodnow (Timothy T)
Anzahl der mitarbeiter117
WertpapierartOrdinary Share
GeschäftsjahresendeMar 04
Addresse20451 Seneca Meadows Pkwy
StadtGERMANTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20876-7005
Telefon13015157260
Websitehttps://www.senseonics.com/
BörsenkürzelSENS
IPO-datumMar 04, 2015
CEOGoodnow (Timothy T)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten